Results 81 to 90 of about 222,862 (245)

QSOX2‐Mediated Disulfide Bond Modification Enhances Tumor Stemness and Chemoresistance by Activating TSC2/mTOR/c‐Myc Feedback Loop in Esophageal Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
High QSOX2 enhances stemness, drug resistance, and metastasis of ESCC cells. QSOX2‐mediated disulfide bond modification activates mTOR/c‐Myc signaling. CAFs‐secreted IGF‐1 drives mTOR/c‐Myc/QSOX2 positive feedback loop. Combining Ebselen, rapamycin, and cisplatin induces tumor dormancy in mice.
Wo‐Ming Chen   +12 more
wiley   +1 more source

EccDNA‐Driven VPS41 Amplification Alleviates Genotoxic Stress via Lysosomal KAI1 Degradation

open access: yesAdvanced Science, EarlyView.
Following ionizing radiation, eccDNA‐mediated VPS41 amplification slightly increases its expression but fails to prevent apoptosis. Introducing exogenous eccDNA or VPS41 enhances VPS41‐KAI1 interaction, promoting lysosomal degradation of KAI1. This process inhibits apoptotic signaling, enhancing cell survival and resistance to radiation‐induced damage.
Bin Shi   +12 more
wiley   +1 more source

Perturbations in neuroinflammatory pathways are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors. [PDF]

open access: yes, 2019
Paclitaxel is a common chemotherapy drug associated with the development of chronic paclitaxel-induced peripheral neuropathy (PIPN). PIPN is associated with neuroinflammatory mechanisms in pre-clinical studies.
Abrams, Gary   +9 more
core  

Paclitaxel Maculopathy [PDF]

open access: yesArchives of Ophthalmology, 2007
Mandar M, Joshi, Bruce R, Garretson
openaire   +2 more sources

PP2A Promotes the Symmetric Division of MUC1‐Dominant Cancer Stem‐Like Cells in Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
During the G2/M phase, mucin1 (MUC1) activates protein phosphatase 2A (PP2A), leading to reduced phosphorylation of protein kinase C ζ (PKCζ) and NUMB, which promotes symmetric division and expansion of cancer stem‐like cells (CSLCs), thereby driving tumorigenesis. Combined inhibition of the MUC1–PP2A axis using LB100/GO203 with etoposide restores PKCζ
Shengze Li   +15 more
wiley   +1 more source

Exosomal CMTM4 Induces Immunosuppressive Macrophages to Promote Ovarian Cancer Progression and Attenuate Anti‐PD‐1 Immunotherapy

open access: yesAdvanced Science, EarlyView.
In ovarian tumors with high CMTM4 expression, exosomes transfer CMTM4 to macrophages, upregulating ICAM1 and promoting M2 polarization via p65 nuclear translocation. This suppresses immunity by increasing PD‐1 and Tregs while reducing CD8+ T cells.
Bo Yin   +12 more
wiley   +1 more source

Precision‐Guided Stealth Missiles in Biomedicine: Biological Carrier‐Mediated Nanomedicine Hitchhiking Strategy

open access: yesAdvanced Science, EarlyView.
Diagram illustrating the binding methods of NPs and biological barriers. The biological carrier‐mediated nanomedicine hitchhiking strategy (BCM‐NHS) utilizes two distinct techniques: the surface‐based “Backpack” method, which relies on ligand‐receptor binding, covalent conjugation, and non‐covalent binding, and the encapsulated “Trojan horse” approach,
Yuyan Zhou   +17 more
wiley   +1 more source

Systemic Therapy in Endometrial Cancer: Recent Advances. [PDF]

open access: yes, 2013
Endometrial cancer is a chemosensitive disease. Studies have established a clear benefit of chemotherapy in advanced stages and trials are ongoing to define its role in early stages as well.
Bhise, R   +5 more
core   +1 more source

Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter retrospective study

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
The effectiveness of intraperitoneal chemotherapy using paclitaxel (i.p.‐PTX) in pancreatic ductal adenocarcinoma (PDAC) patients with peritoneal dissemination remains elusive. This study indicated that the i.p.‐PTX therapy may improve survival in selected patients with PDAC, in particular those with occult peritoneal dissemination.
Tomohisa Yamamoto   +33 more
wiley   +1 more source

A severity‐based tumor‐superior mesenteric/portal vein interface grading criteria as a predictor of survival outcomes in pancreatic head ductal adenocarcinoma patients undergoing pancreaticoduodenectomy following neoadjuvant chemoradiotherapy

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
PDAC patients with the radiological severe interface (≥25 contact length and ≥210 degrees circumferential tumor‐SMV/PV interface) may help predict poor survival outcomes preoperatively. Abstract Aim To assess the ability of a new severity‐based tumor‐superior mesenteric/portal vein interface criteria to predict survival outcomes in pancreatic ductal ...
Benson Kaluba   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy